These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 1685652)
1. Markers for disease progression in intravenous drug users infected with HIV-1. Zangerle R; Fuchs D; Reibnegger G; Fritsch P; Wachter H AIDS; 1991 Aug; 5(8):985-91. PubMed ID: 1685652 [TBL] [Abstract][Full Text] [Related]
2. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191 [TBL] [Abstract][Full Text] [Related]
3. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection. Zangerle R; Fuchs D; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Dierich MP; Möst J Clin Immunol Immunopathol; 1994 Sep; 72(3):328-34. PubMed ID: 7914841 [TBL] [Abstract][Full Text] [Related]
4. Immune serum markers and CD4 cell counts in HIV-infected intravenous drug users. Chaisson RE; Taylor E; Margolick JB; Muñoz A; Solomon L; Cohn S; Nelson KE; Vlahov D J Acquir Immune Defic Syndr (1988); 1992; 5(5):456-60. PubMed ID: 1348535 [TBL] [Abstract][Full Text] [Related]
5. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448 [TBL] [Abstract][Full Text] [Related]
6. Immune activation markers and CD4+ T-cell counts in HIV-infected intravenous drug users. Zangerle R; Wachter H; Fuchs D J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1273-4. PubMed ID: 1360538 [No Abstract] [Full Text] [Related]
7. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. Zangerle R; Steinhuber S; Sarcletti M; Dierich MP; Wachter H; Fuchs D; Möst J Int Arch Allergy Immunol; 1998 Jul; 116(3):228-39. PubMed ID: 9693271 [TBL] [Abstract][Full Text] [Related]
8. [Lymphocyte subpopulations, neopterin, and beta-2-microglobulin: relationship with clinical stage, risk of progression to AIDS and presence of active infection in HIV infection]. Antón F; Labarga P; Pinilla J; Soto MJ; Leoz A; del Cura J; Borque L; Milazzo A Enferm Infecc Microbiol Clin; 1993; 11(7):373-7. PubMed ID: 8104488 [TBL] [Abstract][Full Text] [Related]
9. Immune activation markers and AIDS prognosis. Osmond DH; Shiboski S; Bacchetti P; Winger EE; Moss AR AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808 [TBL] [Abstract][Full Text] [Related]
10. Close relationships between neopterin and beta-2-microglobulin levels in intravenous drug abusers. Lin RY; Nygren E; Valinsky J; Lorenzana FG; Ralph H Int Arch Allergy Appl Immunol; 1990; 91(4):389-93. PubMed ID: 1976599 [TBL] [Abstract][Full Text] [Related]
11. Early levels of CD4, neopterin, and beta 2-microglobulin indicate future disease progression. Shi M; Taylor JM; Fahey JL; Hoover DR; Muñoz A; Kingsley LA J Clin Immunol; 1997 Jan; 17(1):43-52. PubMed ID: 9049785 [TBL] [Abstract][Full Text] [Related]
12. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. Zangerle R; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Fuchs D J Acquir Immune Defic Syndr (1988); 1994 Nov; 7(11):1149-56. PubMed ID: 7932082 [TBL] [Abstract][Full Text] [Related]
13. Neopterin and beta 2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection. Fuchs D; Krämer A; Reibnegger G; Werner ER; Dierich MP; Goedert JJ; Wachter H Infection; 1991; 19 Suppl 2():S98-102. PubMed ID: 1673120 [TBL] [Abstract][Full Text] [Related]
14. Laboratory markers and the risk of developing HIV-1 disease among injecting drug users. Alcabes P; Selwyn PA; Davenny K; Hartel D; Buono D; Schoenbaum EE; Klein RS; Friedland GH AIDS; 1994 Jan; 8(1):107-15. PubMed ID: 7912083 [TBL] [Abstract][Full Text] [Related]
15. Weight loss in HIV-1 infection is associated with immune activation. Zangerle R; Reibnegger G; Wachter H; Fuchs D AIDS; 1993 Feb; 7(2):175-81. PubMed ID: 8096702 [TBL] [Abstract][Full Text] [Related]
16. Urinary neopterin concentrations and T-cell subset data in HIV-1 infection. Reibnegger G; Fuchs D; Goedert JJ; Hausen A; Krämer A; Werner ER; Werner-Felmayer G; Dierich MP; Wachter H Klin Wochenschr; 1990 Jan; 68(1):43-8. PubMed ID: 1968523 [TBL] [Abstract][Full Text] [Related]
17. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. Jacobson MA; Bacchetti P; Kolokathis A; Chaisson RE; Szabo S; Polsky B; Valainis GT; Mildvan D; Abrams D; Wilber J BMJ; 1991 Jan; 302(6768):73-8. PubMed ID: 1671651 [TBL] [Abstract][Full Text] [Related]
18. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection. Lafeuillade A; Tamalet C; Pellegrino P; de Micco P; Vignoli C; Quilichini R J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1028-33. PubMed ID: 7916049 [TBL] [Abstract][Full Text] [Related]
19. A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. Briggs NC; Natoli C; Tinari N; D'Egidio M; Goedert JJ; Iacobelli S AIDS Res Hum Retroviruses; 1993 Sep; 9(9):811-6. PubMed ID: 7504933 [TBL] [Abstract][Full Text] [Related]
20. Early markers of HIV infection and subclinical disease progression. Dolan MJ; Lucey DR; Hendrix CW; Melcher GP; Spencer GA; Boswell RN Vaccine; 1993; 11(5):548-51. PubMed ID: 8098175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]